Abera Bioscience is developing the next generation mucosal vaccines based on our proprietary vaccine delivery platform.
With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.
Abera develops a pipeline of mucosal vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also develops vaccine technologies for pandemic preparedness.
Abera is taking OMV technology to the next level and use it as the basis for development of multiple vaccine candidates suitable for mucosal administration, like nasal spray administration.
Abera combines novel technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking OMV technology to the next level and use it as the basis for development of multiple vaccine candidates suitable for mucosal administration, like nasal spray administration.
Abera combines novel technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Denna artikel är en fördjupning inom pneumokocker och en del i en serie fördjupningsartiklar från Abera Bioscience. Från förskolan till äldreboendet sprids pneumokocker ofta tyst
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2025 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 297 (4 506) kSEK Resultatet efter finansiella poster
Abera Bioscience AB (“Abera” or the “Company”) announces the outcome of the directed issue of units that was announced on 17 July 2025. The issue
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.